Venaxis Inc fka APPY

[newtechinvestor]

Below is the investor presentation of the company.

http://www.aspenbiopharma.com/doc/AspenBio-PPT.pdf

Key highlight:

20% of 6mil "abd pain" cases annually:
1.2mil x $200 (est) = $240mil rev potential in US alone

40% of 6mil given cases:
2.6mil x $200 (est) = $480mil rev potential in US alone

And add potential revenue from animal pharma segment, you have a small pharma in Aspenbio unbelievably outstanding potential. These numbers are written in pencil, but it nonetheless give you outstanding potential.